D. Kim

Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC).

Tony Mok, David R. Spigel, Kanghyun Park et al. · Journal of Clinical Oncology · 2010 · 25 citations

Medicine, Oncology, Pharmacology +7

Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers

Mark G. Kris, Zelanna Goldberg, Pasi A. Jänne et al. · Annals of Oncology · 2012 · 22 citations · Full text

Medicine, Oncology, Pharmacology +16

Updated Safety and Efficacy from a Phase I Study of Azd9291 in Patients (Pts) with Egfr-Tki-Resistant Non-Small Cell Lung Cancer (Nsclc)

James Chih‐Hsin Yang, D. Kim, David Planchard et al. · Annals of Oncology · 2014 · 20 citations · Full text

Medicine, Oncology, Pharmacotherapy +8